Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode. Then today we found out that J&J got a green light from the FDA for its OTTAVA Robotic Surgical System. The OTTAVA CatalystOn July 22, 2026, Johnson & Johnson announced that the U.S. FDA granted De Novo marketing authorization for its OTTAVA Robotic Surgical System. Today’s the day when we’re grateful for our Johnson & Johnson position. Big Money Stance & Minimal Short ExposureInstitutional holders maintain a massive presence in Johnson & Johnson (NYSE:JNJ), with fund holdings accounting for roughly 77% of total shares outstanding.